Moreover, the treatment of L14‐8 in prostate cancer organoids derived from patients who underwent ADT demonstrated a significant induction of cell death compared to the AR antagonist enzalutamide (Figure 2H,I; Figure S1, Supporting Information). Here, AR is linked to prostate cancer.